scout

Podcasts

Recent Episodes

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics
Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics
Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center
Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS
Komal Jhaveri, MD, FACP, breast medical oncologist, Memorial Sloan Kettering Cancer Center
ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
Andrew Lipsky, MD
Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD
Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate
Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate
Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD
Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD
Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Aila
Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD
Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
Multimodality in Oncology: Are We There Yet?
Multimodality in Oncology: Are We There Yet?
Tycel Phillips, MD, associate professor, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope
Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD

All series

Stephen Gottschalk, MD; Giedre Krenciute, PhD

Pediatrics

Career GPS

Marvels in Medicine

Marvels in Medicine

Talking Tumors

Talking Tumors

Scott Kopetz, MD, PhD, FACP, deputy chair, Translational Research, professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, leader, Department of Cancer Center Support Grant, GI Program, TRACTION medical director, Division of Therapeutics Discovery, associate vice president, Translational Integration, The University of Texas MD Anderson Cancer Center

Biomarker Consortium

State of the Science Summits

State of the Science Summits

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Rebecca Porter, MD, PhD, physician, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

CME Podcasts

CME Podcasts

Neil Iyengar, MD, associate professor, Department of Hematology and Medical Oncology, co-director, Breast Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, director, Survivorship Services, Winship Cancer Institute of Emory University; Heather Moore, CPP, PharmD, clinical pharmacist practitioner, Duke Cancer Center Breast Clinic; Sarah Donahue, MPH, NP, nurse practitioner, University of California San Francisco Health

Roundtable Discussions

Samuel A. Kareff, MD, MPH, outgoing chief fellow, hematology and medical oncology, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital

Fellowship

Mariam F. Eskander, MD, MPH

Disparities

Kristen N. Ganjoo, MD, sarcoma specialist, medical oncologist, Stanford Health Care; professor, medicine, Stanford Medicine

Rare Cancers

Liliana Bustamante, MD, medical oncologist, hematologist, Florida Cancer Specialists & Research Institute; Jessica Stine, MD, medical director, Gynecologic Oncology, Florida Cancer Specialists & Research Institute

Women In Oncology

Andrew Lipsky, MD

Conference Perspectives

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin T

OncClub

Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center

Oncology Expert Insights

Lorenzo Falchi, MD, medical oncologist/hematologist, assistant attending physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center

FDA Approval Insights

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine

Blood Club

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois

Two Onc Docs

Girindra Raval, MD; Anand Jillella, MD, J. Harold Harrison, MD Distinguished University Chair in Medicine, professor, medicine & pediatrics, chief, Division of Hematology/Oncology, Augusta University Medical College of Georgia

Cancer, Character, and Calling

D. Ross Camidge, MD, PhD; Justin Call, MD, medical oncologist, hematologist, Utah Cancer Specialists

How This Is Building Me

All Podcasts

Expanding on Emerging Agents in GI Cancers in Dallas

ByOnclive Team

This Dallas, Texas meeting on gastrointestinal (GI) cancers covered emerging therapies in pancreatic cancer, updates in neuroendocrine tumors, the management of metastatic colorectal cancer, recent data in hepatocellular carcinoma, and the clinical application of precision medicine in GI cancers.

Advanced Non-Small Cell Lung Cancer Meeting in Denver

ByOnclive Team

We went out to Denver, Colorado for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer. The conference spanned screening, molecular profiling, early-stage advances, treatment for oncogenic-driven advanced disease, and immunotherapy.

Breast Cancer Meeting in Houston

ByOnclive Team

We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.